basic sceince research

MULTI-CENTER NATIONAL DATABASE PROGRAM

Understanding the Fight Against Prostate Cancer

Currently, little is known about the causes of prostate cancer development. Only advanced age, family history, and race/ethnicity have been established as risk factors for cancer development. There is continued debate over the value of annual PSA screening in asymptomatic men or treatment in men with low risk disease. Such debate can be confusing for patients -- and not all experts agree on these important topics.

Leveraging Programmatic Strengths to Improve Patient Outcomes

The Center for Prostate Disease Research (CPDR) Multi-center National Database Program seeks to longitudinally collect comprehensive demographic, clinical, treatment and quality of life outcomes data to learn more about prostate disease, particularly prostate cancer, in an effort to better prevent, diagnose and treat patients. The database is a highly valuable programmatic resource that enables CPDR researchers to examine patients diagnosed in an equal access health care system, who are characterized by racial/ethnic heterogeneity. Patient data are linked to bio-specimens including urine, serum, and tissue providing opportunity to examine important translational research questions, including biomarkers of disease detection and progression.

 

MISSION

  • Obtain informed consent to enroll men with prostatic diseases for longitudinal follow-up
  • To capture comprehensive clinico-pathologic, demographic, and longitudinal follow-up data including treatment outcomes, as part of routine data collection activities
  • To assess at regular intervals the health-related quality-of-life of patients, along the continuum of prostate disease care
  • To serve as a critical link in support of basic science and clinical science research, providing unprecedented opportunities for translational research
  • To provide a resource for training and education of medical residents and students
  • To provide a national resource for prostate disease researchers, supporting breakthroughs in studies on prostate disease prevention, diagnosis, and treatment

 

Unique attributes of the database include a study population comprised primarily of military health care beneficiaries with comparable access to health care and uniformity in PSA screening and treatment guidelines; an over-representation of African American men, allowing for in-depth examination of the impact of race/ethnicity on prostate cancer outcomes; abundant clinical data necessary to calculate risk factors for disease development and progression, including PSA kinetics (e.g., doubling time, velocity) and obesity; (robust, long term data on health-related quality-of-life outcomes during the period of cancer survivorship; and a civilian site that can serve as an internal control study population.

MNDP Staff Listing | CDPR Sites

CURRENT EVENTS


August 21, 2014

ERG Monoclonal Antibody [9FY] Patent Issued To The Uniformed Services University Of The Health Sciences Center For Prostate Disease Research & Biocare Medical

Concord, CA – The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has been awarded a patent in the United States (Patent No: US 8,765,916 B2) and Europe for ERG monoclonal antibodies. The patent is pending in Australia, Canada and Japan. ERG mouse antibody 9FY is a rigorously characterized antibody for its specificity of the ERG protein detection among the closely related members of the ETS transcription factor family in biological specimens.

Read Full Article

 

August 6, 2014

Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints

Redwood City, CA – PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a ...

Read Full Article

 

WRNMMC UsToo! Newsletter

Read the AUGUST 2014 Newsletter